ITP Access

For your adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment

ACCESS DOPTELET® (avatrombopag): DOVA 1SOURCE

A range of healthcare navigation support and financial assistance to help your patients

Dova® 1Source™

 

Dova 1Source can help your prescribed patients navigate access at any point through the fulfillment process.

 

Dedicated Care Coordinators can help:

 

Research your patient’s individual coverage for DOPTELET

 

Coordinate with an eligible specialty pharmacy to fill your patient’s prescription

 

Connect your patients with affordability options if needed. Patients must meet eligibility criteria

 

For more information and to access enrollment forms:

Or

Please call 1-833-DOVA-ONE (1-833-368-2663)

Care Coordinators are available Monday–Friday 8 AM–8 PM EST

About DOPTELET® (avatrombopag)

Learn how DOPTELET works with the body to increase platelet counts.1

Reference:

1. DOPTELET [package insert]. Durham, NC: Dova Pharmaceuticals, Inc.

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION FOR DOPTELET

Warnings and Precautions

DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic immune thrombocytopenia. Thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

In clinical trials, 7% (9/128) of patients with chronic immune thrombocytopenia treated with DOPTELET developed a thromboembolic event. Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).

DOPTELET should not be administered to patients with chronic immune thrombocytopenia in an attempt to normalize platelet counts. Follow the dosing guidelines to achieve target platelet counts.

Contraindications:  None

Drug Interactions  

Dose adjustments are recommended for patients with chronic immune thrombocytopenia taking moderate or strong dual CYP2C9 and CYP3A4 inducers or inhibitors.

Adverse Reactions

The most common adverse reactions (≥10%) were: headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae and nasopharyngitis.

Please see Full Prescribing Information for DOPTELET® (avatrombopag).

Visit Dova.com for WAC pricing.

 
 

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION FOR DOPTELET

Warnings and Precautions

DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic immune thrombocytopenia. Thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.